Literature DB >> 32433395

Radioligand Theranostics in the Management of Neuroendocrine Tumors.

Alan G Harris1, Aaron I Vinik2, Thomas M OʼDorisio3, M Sue OʼDorisio4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32433395      PMCID： PMC7700749          DOI： 10.1097/MPA.0000000000001546

Source DB:  PubMed          Journal:  Pancreas        ISSN： 0885-3177            Impact factor:   3.327


× No keyword cloud information.
  40 in total

1.  Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.

Authors:  J Rubin; J Ajani; W Schirmer; A P Venook; R Bukowski; R Pommier; L Saltz; P Dandona; L Anthony
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

2.  Somatostatin receptors in human endocrine tumors.

Authors:  J C Reubi; R Maurer; K von Werder; J Torhorst; J G Klijn; S W Lamberts
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

3.  Somatostatin-receptor imaging in the localization of endocrine tumors.

Authors:  S W Lamberts; W H Bakker; J C Reubi; E P Krenning
Journal:  N Engl J Med       Date:  1990-11-01       Impact factor: 91.245

Review 4.  Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects.

Authors:  Gherardo Mazziotti; Alessandra Mosca; Stefano Frara; Giovanni Vitale; Andrea Giustina
Journal:  Expert Opin Pharmacother       Date:  2017-10-25       Impact factor: 3.889

Review 5.  An introduction to the clinical practice of theranostics in oncology.

Authors:  J Harvey Turner
Journal:  Br J Radiol       Date:  2018-09-04       Impact factor: 3.039

Review 6.  An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases.

Authors:  Anna Lucia Tornesello; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Mini Rev Med Chem       Date:  2017       Impact factor: 3.862

7.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Authors:  L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05       Impact factor: 9.236

Review 8.  Evolution of Neuroendocrine Tumor Therapy.

Authors:  Thomas M O'Dorisio; Alan G Harris; M Sue O'Dorisio
Journal:  Surg Oncol Clin N Am       Date:  2020-04       Impact factor: 3.495

9.  Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors.

Authors:  Simone Krebs; Neeta Pandit-Taskar; Diane Reidy; Bradley J Beattie; Serge K Lyashchenko; Jason S Lewis; Lisa Bodei; Wolfgang A Weber; Joseph A O'Donoghue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-29       Impact factor: 9.236

Review 10.  Development of Targeted Alpha Particle Therapy for Solid Tumors.

Authors:  Narges K Tafreshi; Michael L Doligalski; Christopher J Tichacek; Darpan N Pandya; Mikalai M Budzevich; Ghassan El-Haddad; Nikhil I Khushalani; Eduardo G Moros; Mark L McLaughlin; Thaddeus J Wadas; David L Morse
Journal:  Molecules       Date:  2019-11-26       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.